Patients with a history of alcohol problems face extreme difficulty or outright refusals from psychiatrists when trying to obtain standard stimulant prescriptions for ADHD due to strict risk-assessment policies and fears of misuse.
Patients with a history of alcohol problems face extreme difficulty or outright refusals from psychiatrists when trying to obtain standard stimulant prescriptions for ADHD due to concerns over misuse, diversion, and physical health risks.
Doctors and ADHD meds after a history of alcohol problems — what's actually standard practice?
Active addiction is not a road to a healthy life and there is zero evidence to Drs that the patient wouldn't abuse the medication to 'self medicate'.
commentI'm a recovering addict with 10 years sobriety, I'm also diagnosed AuDHD/CPTSD so I can perhaps answer from my experiences with Drs, my history of addiction and the damage to my body from decades of addiction and how Drs view the risks. Active addiction with substance abuse is incredibly damaging to your heart amongst other vital organs, the main concern being the heart. Prescription amphetamine is no different, its still an addictive drug that does the same thing just legally. Any drug in the hands of someone in active addiction is just swapping one for another, you need to address the elephant in the room so to speak. The point of medication to become well, or at least reduce the symptoms of a disease to where it's manageable to live a healthy life. Active addiction is not a road to a healthy life and there is zero evidence to Drs that the patient wouldn't abuse the medication to "self medicate". I've been there, I've been judged and I worked hard to build trust with Drs. I get it. My heart is the main concern, it's had a rough life. I have to take my BP regularly and send the results to my Dr. They do not mess around with cardiology, it's like the number 1 thing my Dr has zero humour about and rightly so. He wouldn't hesitate to take me off my medication if my heart required it regardless of my symptoms. It means I need to be serious about my health. When I was diagnosed originally I had been sober for 2 years. Ironically, now I forget to take my meds if I'm not reminded. I've not tried any other variants of medication except Dex so I can't offer anything on that. It's an interesting system to navigate when you have a history of addiction. Hope that word salad helped.
it comes down to doctors weighing up the risks and the consequences of prescribing these medications, will they do more harm than good?
commentAbsolutely NOT a medical professional in any way, shape, or form BUT my guess? Alcoholism is still substance abuse and it's a substance abuse which comes with a lot of side effects and poor health. Stimulants are not very kind on the body, some of them have side effects like psychosis and mania at their worst so I would assume mixing them with a body and brain already coping with the effects of alcoholism isn't good. They do also put a bit of an extra strain on your liver and again, if your liver is already under strain due to excessive alcohol, it can have a compounding effect. There's also the potential abuse of stimulants with alcoholism. There's a reason people sell their meds at nightclubs and to friends, even if you do have ADHD, if you take enough they'll keep you up and moving all night even as you're downing half the bottle shop. Or, if money is tight and the liquor cabinet empty, will you sell those meds to fund your addiction? In the end it comes down to doctors weighing up the risks and the consequences of prescribing these medications, will they do more harm than good? And then deciding if they're willing to carry the responsibility.
Individuals with past alcohol abuse who are in long-term sobriety and face blanket psychiatric rejections for stimulant-based ADHD treatment.
Repeated emphasis across discussions that medical professionals universally fear stimulant misuse and cardiovascular risks in patients with past alcohol problems, creating an absolute barrier to treatment.
Purpose-built specifically to bridge the communication and trust gap between patients in recovery and cautious psychiatrists hesitant to prescribe controlled substances.
A verifiable medical data-logging platform that compiles sobriety records, cardiovascular metrics, and structured accountability reports into a secure packet specifically designed to satisfy psychiatric compliance requirements.
Patients face months of delays and life disruptions from untreated ADHD; $19/mo is a low-friction investment to systematically compile the clinical proof needed to unlock medical care.
“Build clinical trust and secure your ADHD treatment plan with verified sobriety logs.”
A verifiable medical data-logging platform that compiles sobriety records, cardiovascular metrics, and structured accountability reports into a secure packet specifically designed to satisfy psychiatric compliance requirements.
Target recovery and ADHD support communities on Reddit (r/ADHD, r/stopdrinking) through educational resources and case studies on navigating psychiatric evaluations.
Psychiatrists may distrust external tracking tools or require official institutional testing rather than patient-compiled logs.
Handling highly sensitive substance abuse and medical records requires strict adherence to privacy regulations.
Once a patient successfully secures their prescription, they may immediately cancel their subscription.
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoThis idea scores in the upper-middle range of opportunities surfaced by MonetScope, with a validation sub-score of 8/10 against 3 independently sourced evidence signals. A "promising" rating usually indicates a real pain has been detected and discussed in the open, but the pipeline did not find enough signal to flag it as urgent or high-frequency. These opportunities can still produce excellent businesses — they often correspond to "boring" problems that established players have ignored — but the founder should expect a longer customer-development cycle to confirm willingness to pay.
It sits at the intersection of "compliance", "data-management", "healthcare", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.
